Danaher Corporation vs Vanguard Total Stock Market Index Fund ETF — how do they compare? Danaher Corporation trades at $198.81 (market cap $140.88B), while Vanguard Total Stock Market Index Fund ETF trades at $371.48. The key difference: Danaher Corporation pays a 0.8% dividend while Vanguard Total Stock Market Index Fund ETF pays none, and Vanguard Total Stock Market Index Fund ETF is trading nearer its 52-week high, Danaher Corporation nearer its low. Which is the better fit depends on your goals.
| DHR | VTI | |
|---|---|---|
Market Cap | $140.88B | — |
Sector | Health | — |
52-Week High | $242.05 | $374.36 |
52-Week Low | $161.91 | $305.74 |
Enterprise Value | $153.66B | — |
Dividend Yield | 0.8% | — |
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $200.16, up 0.56% today, with a bullish technical signal from moving averages and strong analyst support. The company reported Q1 2026 EPS of $2.06, beating estimates of $1.94, marking the third consecutive quarterly beat. Revenue for 2025 was $24.57 billion with a net income margin of 14.89%, though margins have compressed from prior years. Recent news includes the acquisition of Masimo and a $172.5 million legal settlement finalized in April 2026.
The outlook remains positive with a consensus price target of $211.33, implying ~5.6% upside, supported by 69% buy ratings. Key risks include margin pressure, integration challenges from acquisitions, and macroeconomic sensitivity. The stock offers a dividend yield from its $0.40 quarterly payout, with solid cash flow generation offsetting debt levels.
VTI trades at $369.78, down 0.78% on the day, with a bullish technical signal supported by moving averages. The ETF provides comprehensive U.S. market exposure with over 3,400 stocks and an ultra-low 0.03% expense ratio. Recent news highlights its inclusion in new Trump Accounts and strong long-term performance history averaging nearly 10% annual returns over 25 years.
VTI offers diversified U.S. equity exposure with minimal costs, though its performance remains tied to broader market volatility. Key risks include economic downturns and interest rate sensitivity, while institutional adoption and positive media sentiment support its long-term appeal for core portfolio holdings.
Trailing returns across standard periods
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →The fund employs an indexing investment approach designed to track the performance of the index, which represents approximately 100% of the investable US stock market and includes large-, mid-, small-, and micro-cap stocks. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the full index in terms of key characteristics.
Read more on VTI →